Editor's Note :

Editor's Note :

There is a possibility of opinions on Wednesday, January 18, at 10:00 a.m. We will begin live-blogging at this link at 9:45 a.m.
On Wednesday the court hears oral argument in Lee v. Tam. Amy Howe has our preview.
On Wednesday the court also hears oral argument in Ziglar v. Abbasi. Amy Howe has our preview.

Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S

Docket No. Op. Below Argument Opinion Vote Author Term
10-844 Fed. Cir. Dec 5, 2011
Tr.Aud.
Apr 17, 2012 9-0 Kagan OT 2011

Holding: A generic drug manufacturer may employ the counterclaim provision of the Hatch-Waxman Act to force correction of a use code that inaccurately describes the brand’s patent as covering a particular method of using a drug.

Judgment: Reversed and remanded, 9-0, in an opinion by Justice Kagan on April 17, 2012. Justice Sotomayor filed a concurring opinion.

SCOTUSblog Coverage

Briefs and Documents

Merits Briefs for Petitioners

Amicus Briefs Supporting Petitioners

Merits Briefs for the Respondents

Amicus Briefs Supporting the Respondents

Certiorari-stage documents

 
Share:
Term Snapshot
Awards